A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Je Vrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Purpose: Peptide antigens have been administered by different approaches as cancer vaccine therapy, including direct injection or pulsed onto dendritic cells; however, the optimal delivery method is still debatable. In this study, we describe the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. Experimental design: Twenty-one HLA-A2.1 patients with stage III, IV, or recurrent ovarian cancer over-expressing the p53 protein with no evidence of disease were treated in two cohorts. Arm A received SC wt p53:264-272 peptide admixed with Montanide and GM-CSF. Arm B received wt p53:264-272 peptide-pulsed dendritic cells IV. Interleukin-2 (IL-2) was administered to both cohorts in alternative cycles. Results: Nine of 13 patients (69%) in arm A and 5 of 6 patients (83%) in arm B developed an immunologic response as determined by ELISPOT and tetramer assays. The vaccine caused no serious systemic side effects. IL-2 administration resulted in grade 3 and 4 toxicities in both arms and directly induced the expansion of T regulatory cells. The median overall survival was 40.8 and 29.6 months for arm A and B, respectively; the median progression-free survival was 4.2 and. 8.7 months, respectively. Conclusion: We found that using either vaccination approach generates comparable specific immune responses against the p53 peptide with minimal toxicity. Accordingly, our Wndings suggest that the use of less demanding SC approach may be as effective. Furthermore, the use of low-dose SC IL-2 as an adjuvant might have interfered with the immune response. Therefore, it may not be needed in future trials.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume61
Issue number3
DOIs
StatePublished - Mar 1 2012

Keywords

  • Cancer vaccine
  • IL-2
  • Ovarian cancer
  • p53

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Rahma, O. E., Ashtar, E., Czystowska, M., Szajnik, M. E., Wieckowski, E., Bernstein, S., Herrin, V. E., Shams, M. A., Steinberg, S. M., Merino, M., Gooding, W., Visus, C., DeLeo, A. B., Wolf, J. K., Bell, J. V. G., Berzofsky, J. A., Whiteside, T. L., & Khleif, S. N. (2012). A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy, 61(3), 373-384. https://doi.org/10.1007/s00262-011-1100-9